Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Imperial College London |
---|---|
Information provided by: | Imperial College London |
ClinicalTrials.gov Identifier: | NCT00159380 |
The primary aim of this study is to investigate the effects of oral and inhaled administration of L-arginine and of inhaled aminoguanidine on bronchial and alveolar exhaled NO and NO metabolites in exhaled breath condensate, saliva and nasal lavage fluid in normal and asthmatic subjects.
Condition | Intervention |
---|---|
Asthma |
Procedure: Inhalation of aminoguanidine and oral intake and inhalation of L-arginine Procedure: Exhaled Breath Condensate Procedure: Nasal Lavage Procedure: Saliva Procedure: Spirometry |
Study Type: | Interventional |
Study Design: | Randomized, Double-Blind, Placebo Control, Crossover Assignment |
Official Title: | A Double Blind, Crossover Placebo-Controlled Study to Evaluate the Effect of L-Arginine and Aminoguanidine on Bronchial, Alveolar and Nasal NO and NO Metabolites in Exhaled Air, Breath Condensate, Saliva, Nasal Lavage Fluid and Induced Sputum in 10 Normal and 15 Asthmatic Subjects |
Ages Eligible for Study: | 21 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Healthy non-smokers (n=10):
Asthmatic subjects (n=15):
Exclusion Criteria:
United Kingdom | |
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital | |
London, United Kingdom, SW3 6LY |
Principal Investigator: | Sergei A Kharitonov, MD, PhD | Imperial College London |
Study ID Numbers: | 2002AT033B |
Study First Received: | September 9, 2005 |
Last Updated: | April 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00159380 |
Health Authority: | United Kingdom: Research Ethics Committee |
Healthy Volunteers |
Nitric Oxide Asthma Healthy Pimagedine |
Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Pharmacologic Actions |